Doubt over the long-term health benefit of stimulating insulin release per se as a route to reducing PPG is indicated by data from Nateglinide, a drug stimulating insulin release, that was found ineffective in reducing the transition from pre-diabetes to diabetes [15]. This evidence concerns the gene INS and diabetes mellitus.